ABBV AbbVie Inc.

bullish · high conviction track record → $213.12 -2.58 (-1.2%)
Mkt Cap $375B P/E 104.1 fwd 13.1 52wk $180.25 - $244.81 7d ago
Est. revisions: +0.5% (10 up, 7 down in 30d)
Factor Model (net +1.0)

Factor Model

net +1.0 3.4 / 10
Est. Revisions
+0.0
Insider Activity
+0.0
Momentum
+0.5
Analyst Rev.
+0.3
Narrative Gap
+0.0

AbbVie Wins Hep C Nod, Dividend Streak Shines

Watch: Next earnings release to track Maviret impact and progress in mid/late-stage pipeline.

AbbVie won a positive CHMP opinion for Maviret to treat acute hepatitis C, boosting market potential. Shares rose 0.6% to $215.70 on this news. The company boasts a 53-year dividend increase streak and a forward yield above 3.2%, supported by a strong pipeline with 90+ programs and growth in drugs like Skyrizi and Rinvoq.

The positive regulatory development and reliable dividends reinforce AbbVie's investment appeal amid its transition post-Humira patent loss.

Evidence

7d ago GE Vernova, Estée Lauder, A Health Care Stock And More On CNBC's 'Final Trades' benzinga
8d ago 3 Monster Dividend Stocks to Hold for the Next 10 Years yahoo-finance
12d ago Tech turmoil: Semiconductor stocks slide, healthcare finds footing - TradingView google-news-semiconductor
14d ago AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI yahoo-finance
17d ago Evercore ISI Group main ABBV: Outperform → Outperform
18d ago Piper Sandler main ABBV: Overweight → Overweight
29d ago Evercore ISI Group main ABBV: Outperform → Outperform
31d ago Bank of America Upgrades AbbVie (ABBV) on Skyrizi Strength, Lifts PT yahoo-finance
7 older signals
32d ago Guggenheim reit ABBV: Buy → Buy
32d ago Morgan Stanley main ABBV: Overweight → Overweight
32d ago Canaccord Genuity main ABBV: Buy → Buy
33d ago Cantor Fitzgerald reit ABBV: Overweight → Overweight
33d ago Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
34d ago AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
36d ago AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
Fundamentals & Data ▾
AbbVie Inc. Healthcare · Drug Manufacturers - General
Mkt Cap
$375B
P/E
104.1 fwd 13.1
Beta
0.30
Div Yield
326.00%
52w Range
$180.25 - $244.81
Short Interest
20.9M 1.32%
Days to Cover
3.0 +4%
Technicals mixed
vs 20d MA
+4.0%
from 52w Hi
0.0%
Vol (20d)
23%
1w return
+2.5%
1m return
+7.3%
Vol ratio
0.9x
Insiders
selling 0B / 2S
Analysts
bullish 1 up / 0 down
EPS Estimate
$3.77 +0.5% 30d 10up / 7dn
Est. Dispersion
6% 21 analysts
Analyst Target
$253 $184 - $328
Options P/C
0.45
Fund Convergence
strong D.E. Shaw, Citadel, Two Sigma, Bridgewater
Financials
Revenue
$15.0B +12% YoY
FCF
$3.6B
Gross Margin
72%
Op Margin
32%
Momentum: decelerating
Top Holders
D.E. Shaw $3.4B
Citadel $960M
Two Sigma $38M
Bridgewater $3M
Recent Filings & Data
insider trade 11
net selling
11 insiders · 11 transactions (30d)
Recent transactions
FALK THOMAS J · award
ROBERTS REBECCA B. · award
RAPP EDWARD J · award
HART BRETT J · award
FREYMAN THOMAS C · award
DAVIS JENNIFER L · award
QUAGGIN SUSAN E · award
BURNSIDE WILLIAM H L · award
MEYER MELODY B · award
AUSTIN ROXANNE SCHUH · award
WADDELL FREDERICK H · award
Track Record (1/1 correct) ▾

Direction History

1/1 correct at 5 days
2026-04-24 bullish +4.0% ✓
Full track record across all stocks →
15 signals · latest 7d ago

Keep reading the market

Direction shifts, insider clusters, filing red flags, and earnings call changes stay published on the site.

All stocks → Track record → How it works →